Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

n-Lorem Foundation

ClinicalTrials.gov lists n-Lorem Foundation as lead sponsor of 17 trials. It has 10 active development programs.

Other
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Disease areas Disease areas 4 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 3 Active development programs Active development programs 10 Sponsor delivery record Sponsor delivery record 1 Organization relationships Organization relationships 1 Latest dated events Latest dated events 19 Biomarker capability evidence Biomarker capability evidence 22 Disease areas Disease areas 4 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 3 Active development programs Active development programs 10 Sponsor delivery record Sponsor delivery record 1 Organization relationships Organization relationships 1 Latest dated events Latest dated events 19 Biomarker capability evidence Biomarker capability evidence 22

Rows recorded per section (log scale)

17 sections measured, none recorded

This page covers n-Lorem Foundation: 17 lead-sponsored trials and 0 legal-entity registrations.

Get the n-Lorem Foundation report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (4)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Amyotrophic Lateral Sclerosis 7
Epilepsies, Myoclonic 3
Epilepsy 3
Myoclonic Epilepsies, Progressive 3

Trials by start year as sponsor or collaborator (3)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 4
2025 7
2024 8

No forecast is made for this organization: it averages 3.6 trial starts a year over the five years to September, under the 5 a year the method needs.

Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

Active development programs (10)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
nL-CHCHD-001 Amyotrophic Lateral Sclerosis Phase 1/2 4
nL-ATN1-002 Epilepsies, Myoclonic Phase 1/2 2
nL-ATN1-002 Myoclonic Epilepsies, Progressive Phase 1/2 2
nL-ATN1-002 Epilepsy Phase 1/2 2
nL-TARDB-006 Amyotrophic Lateral Sclerosis Phase 1/2 1

Showing 5 of 10 active programs.

Start your 14-day trial Email me all 10 active programs as a PDF

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
1 of 1 hit target (n=1) 0 of 1 on time (n=1)

Organization relationships (1)

Organization relationships
Related organization Relationship Evidence
The Methodist Hospital Research Institute Co sponsors trial with 1

Latest dated events (19)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-12 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-04 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-03 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-02-19 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-11-06 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Showing 5 of 19 events.

Start your 14-day trial Email me all 19 events as a PDF

Biomarker capability evidence (22)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ASXL3 Trial sponsor Named in trial inclusion criteria
ATN1 Trial sponsor Named in trial inclusion criteria
ATN1 Trial sponsor Named in trial inclusion criteria
ATN1 Trial sponsor Named in trial inclusion criteria
GARS1 Trial sponsor Named in trial inclusion criteria

Showing 5 of 22 evidence rows.

Start your 14-day trial Email me all 22 evidence rows as a PDF

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, journals published in, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.